Chapter 3
Olmesartan Medoxomil: An Angiotensin II Receptor Blocker
Hiroaki Yanagisawa,
Hiroyuki Koike,
Shin-Ichiro Miura,
Hiroaki Yanagisawa
R&D Division, DAIICHI SANKYO Co., Ltd., Shinagawa-ku, Tokyo, Japan
Search for more papers by this authorHiroyuki Koike
R&D Division, DAIICHI SANKYO Co., Ltd., Shinagawa-ku, Tokyo, Japan
Search for more papers by this authorShin-Ichiro Miura
Department of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan
Search for more papers by this authorHiroaki Yanagisawa,
Hiroyuki Koike,
Shin-Ichiro Miura,
Hiroaki Yanagisawa
R&D Division, DAIICHI SANKYO Co., Ltd., Shinagawa-ku, Tokyo, Japan
Search for more papers by this authorHiroyuki Koike
R&D Division, DAIICHI SANKYO Co., Ltd., Shinagawa-ku, Tokyo, Japan
Search for more papers by this authorShin-Ichiro Miura
Department of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan
Search for more papers by this authorBook Editor(s):Xianhai Huang, Robert G. Aslanian,
Summary
This chapter contains sections titled:
-
Background
-
The Discovery of Olmesartan Medoxomil (Benicar)
-
Characteristics of Olmesartan
-
Binding Sites of Omlersartan to the AT1 Receptor and Its Inverse Agonoist Activity
-
Practical Preparation of Olmesartan Medoxomil
-
Preclinical Studies
-
Clinical Studies
-
Conclusion
-
References
REFERENCES
- The Scientific Meeting of the 21st International Society of Hypertension, October 15–19 2006, at Hukuoka, Japan.
- MOSER, M. The Treatment of Hypertension, 2nd ed., Le Jacq Communications, Inc., Darien, CT, 2002, pp. 1–10.
- ONDETTI, M. A., RUBIN, B., and CUSHMAN, D. W. Design of specific inhibitor of angiotensin converting enzyme. A new class of orally active antihypertensive agents. Science 1977, 196, 441–444.
- BUMPUS, F. M., CATT, K. J., CHIU, A. T., DE CASPARO, M., GOODFRIEND, T., HUSAIN, A., PEACH, M. J., TAYLOR, D. J., and TIMMERMANS, P. B. M. W. M. Nomenclature for angiotensin receptors. A report of the Nomenclature Committee of the Council for High Blood Pressure Research. Hypertension 1991, 17, 720–721.
- NAKA, T., KUBO, K., NISHIKAWA, K., INADA, Y., and FURUKAWA, Y. Angiotensin II receptor antagonists: candesartan cilexetil. Yakugaku Zasshi 2000, 120, 1261–1275.
- (a) FURUKAWA, Y., KISHIMOTO, S., and NISHIKAWA, K. Imidazole derivatives, their production and use. EP Patent 0028833, 1981. (b) FURUKAWA, Y., KISHIMOTO, S., and NISHIKAWA, K. Imidazole-5-acetic acid derivatives, their production and use. EP Patent 0028834, 1981.
- JOHNSON, A. L., CARINI, D. J., CHIU, A. T., DUNCIA, J.V., PRICE, W. A., JR., WELLS, G. J., WEXLER, R. R., WONG, P. C., and TIMMERMANS, P. B. M. W. M. Nonpeptide angiotensin II receptor antagonists. Drug NewsPerspects 1990, 3, 337–351.
- DANCIA, J. V., CHIU, A. T., CARINI, D. J., GREGORY, G. B., JOHNSON, A. L., PRICE, W. A., WELLS, G. J., WONG, P.C., CALABRESE, J. C., and TIMMERMANS, P.B. M.W. M. The discovery of potent nonpeptide angiotensin II receptor antagonists: a new class of potent antihypertensives. J. Med. Chem. 1990, 33, 1312–1329.
- CARINI, D. J., DANCIA, J. V., JOHNSON, A. L., CHIU, A. T., PRICE, W. A., WONG, P. C., and TIMMERMANS, P.B.M.W. M. Nonpeptide angiotensin II receptor antagonists: N[(benzyloxy)benzyl]imidazoles and related compounds as potent antihypertensives. J. Med. Chem. 1990, 33, 1330–1336.
- CARINI, D. J., DANCIA, J. V., ALDRICH, P. E., CHIU, A. T., JOHNSON, A. L., PIERCE, M. E., PRICE, W. A., SANTELLAIII, J. B., WELLS, G. J., WEXLER, R. R., WONG, P. C., YOO, S.-E., and TIMMERMANS, P. B. M. W. M. Nonpeptide angiotensin II receptor antagonists: the discovery of a series of N-(biphenylmethyl)imidazoles as potent, orally active antihypertensives. J. Med. Chem, 1991, 34, 2525–2547.
- CARINI, D. J., CHIU, A. T., WONG, P. C., JOHNSON, A. L., WEXLER, R. R., and TIMMERMANS, P.B.M. W.M. The preparation of (perfluoroalkyl)imidazoles as nonpeptide angiotensin II receptor antagonists. Bioor. Med. Chem. Lett. 1993, 13, 895–898.
- YANAGISAWA, H., AMEMIYA, Y., KANAZAKI, T., SHIMOJI, Y., FUJIMOTO, K., KITAHARA, Y., SADA, T., MIZUNO, M., IKEDA, M., MIYAMOTO, S., FURUKAWA, Y., and KOIKE, H. Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds. J. Med. Chem. 1996, 39, 323–338.
- WONG, P. C., PRICE, W. A., CHIU, A. T., DUNCIA, J.V., CARINI, D. J., WEXLER, R. R., JOHNSON, A. L., and TIMMERMANS, P. B. M. W. M. Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of Dup 753, an orally active antihypertensive agent. J. Pharmacol. Exp. Ther., 1990, 255, 211–217.
- CHO, A. Recent advances in oral prodrug discovery. Annu. Rep. Med. Chem., 2006, 41, 395–407.
- QIN, Y., YASUDA, N., AKAZAWA, H., ITO, K., KUDO, Y., LIAO, C., YAMAMOTO, R., MIURA, S., SAKU, K., and KOMURO, I. Multivalent ligand–receptor interactions elicit inverse agonist activity of AT1 receptor blockers against stretch-induced AT1 receptor activation. Hypertens. Res., 2009, 32, 875–883.
- LE, M. T., PUGSLEY, M. K., VAUQUELIN, G., and LIEFDE, I.V. Molecular characterization of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptor. Br. J. Pharmacol. 2007, 151, 952–962.
- MIURA, S., FUJINO, M., HANZAWA, H., KIYA, Y., IMAIZUMI, S., MATSUO, Y., TOMITA, S., UEHARA, Y., KARNIK, S.S., YANAGISAWA, H., KOIKE, H., KOMURO, I., and SAKU, K. Molecular mechanism underlying inverse agonist of angiotensin II type receptor. J. Biol. Chem., 2006, 281, 19288–19295.
- YATABE, J., SANADA, H., SASAKI YATABE, M., HASHIMOTO, S., YONEDA, M., FELDER, R. A., JOSE, P. A., and WATANABE, T. Angiotensin II type 1 receptor blocker attenuates the activation of ERK and NADPH oxidase by mechanical strain in mesangial cells in the absence of angiotensin II. Am. J. Renal Physiol., 2009, 296, F1052–F1060.
- KAMIYAMA, E., YOSHIGAE, Y., KASUYA, A., TAKEI, M., KURIHARA, A., and IKEDA, T. Inhibitory effects of angiotensin receptor blockers on CYP2C9 activity in human liver microsomes. Drug Metab. Pharmacokinet., 2007, 22, 267–275.
- FENG, Y. -H., NODA, K., SAAD, Y., LIU, X-P., HUSAIN, A., and KARNIK, S.S. The docking of Arg2 of angiotensin II with Asp281 of AT1 receptor is essential for full agonism. J. Biol. Chem., 1995, 270, 12846–12850.
- NODA, K., SAAD, Y., and KARNIK, S. S. Interaction of Phe8 of angiotensin II with Lys199 and His256 of AT1 receptor in agonist activation. J. Biol. Chem., 1995, 270, 28511–28514.
- MIURA, S., FENG, Y. -H., HUSAIN, A., KARNIK, S. S. Role of aromaticity of agonist switches of angiotensin II in the activation of the AT1 receptor. J. Biol. Chem., 1999, 274, 7103–7110.
- SHABMBYE, H. T., HJORTH, S. A., BERGSMA, D. J., SATHE, G., and SCHWARTZ, T. W. Differentiation between binding sites for angiotensin II and nonpeptide antagonists on the angiotensin II type 1 receptors. Proc. Natl. Acad. Sci. USA, 1994, 91, 7046–7050.
- MIURA, S., KIYA, Y., KANAZAWA, T., IMAIZUMI, S., FUJINO, M., MATSUO, Y., KARNIK S. S., and SAKU, K. Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state. Mol. Endocrinol., 2008, 22, 139–146.
- BALEANU-GOGONEA, C., and KARNIK, S. Model of the whole rat AT1 receptor and the ligand-binding site. J. Mol. Model., 2006, 12, 325–337.
- MIZUNO, M., SADA, T., IKEDA, M., FUKUDA, N., MIYAMOTO, M., YANAGISAWA, H., and KOIKE, H. Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. Eur. J. Pharmacol., 1995, 285, 181–188.
- KOIKE, H., KONSE, T., SADA, T., IKEDA, T., HYOGO, A., HINMAN, D., SAITO, H., and YANAGISAWA, H. Olmesartan medoxomil, a novel potent angiotensin II blocker. Annu. Rep. Sankyo Res. Lab., 2003, 55, 1–99.
- KOIKE, H., SADA, T., and MIZUNO, M. In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist. J. Hypertens., 2001, 19 (suppl 1), S3–S14.
- GOODFRIEND, TL. Angiotensins: actions and receptors. In Hypertension Primer, 4th ed. (eds J.L. Izzo, Jr., H.R. Black), Lippincott Wilkins, New York, 2008, pp. 54–58.
- SHAO, J., NANGAKU, M., MIYATA, T., INAGI, R., YAMADA, K., KUROKAWA, K., and FUJITA, T. Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury. Hypertension, 2003, 42, 31–38.
- KIM, S., IZUMI, Y., IZUMIYA, Y., ZHAN, Y., TANIGUCHI, M., and IWAO, H. Beneficial effects of combined blockade of ACE and AT1 receptor on intimal hyperplasia in balloon-injured rat artery. Arterioscler. Thromb. Vasc. Biol., 2002, 22, 1299–1304.
- MUKAI, Y., SHIMOKAWA, H., HIGASHI, M., MORIKAWA, K., MATOBA, T., HIROKI, J., KUNIHIRO, I., TALKDER, H. M. A., and TAKESHITA, A. Inhibition of renin-angiotensin system ameliorates endothelial dysfunction associated with aging in rats. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 1445–1450.
- KATO, T., NASU, T., SONODA, H., ITO, K. M., IKEDA, M., and ITO K., Evaluation of olmesartan medoxomil in the rat monocrotaline model of pulmonary hypertension. J. Cardiovasc. Pharmacol., 2008, 51, 18–23.
- KATO, M., SADA, T., MIZUNO, M., KITAYAMA, K., INABA, T., and KOIKE, H. Effect of combined treatment with an angiotensin II receptor antagonist and an HMG-CoA reductase inhibitor on atherosclerosis in genetically hyperlipidemic rabbits. J. Cardiovasc. Pharmacol., 2005, 46, 556–562.
- KATO, M., SADA, T., CHUMA, H., MIZUNO, M., TERASHIMA, H., FUKUSHIMA, Y., and KOIKE, H. Severity of hyperlipidemia does not affect antiatherosclerotic effect of an angiotensin II receptor blocker in apolipoprotein E-deficient mice. J. Cardiovasc. Pharmacol., 2006, 47, 764–769.
- TAKAI, S., JIN, D., SAKAGUCHI, M., MURAMATSU, M., and MIYAZAKI, M. The regressive effect of an angiotensin receptor blocker on formed fatty streaks in monkeys fed a high-cholesterol diet. J. Hypertens., 2005, 23, 1879–1886.
- MIZUNO, M., SADA, T., KATO, M., and KOIKE, H. Renoprotective effects of blockade of angiotensin II AT1 receptors in an animal model of type 2 diabetes. Hypertens. Res., 2002, 25, 271–278.
- MIZUNO, M., SADA, T., KATO, M FUKUSHIMA, Y., TERASHIMA, H., and KOIKE, H. The effect of angiotensin II receptor blockade on an end-stage renal failure model of type 2 diabetes. J. Cardiovasc. Pharmacol., 2006, 48, 135–142.
- NANGAKU, M., MIYATA, T., SADA, T., MIZUNO, M., INAGI, R., UEDA, Y., ISHIKAWA, N., YUZAWA, H., KOIKE, H., VAN YPERSELE DE STRIHOU, C., and KUROKAWA, K. Antihypertensive agents inhibit in vivo the formation of advanced glycation end product and improve renal damage in a type 2 diabetic nephropathy rat model. J. Am. Soc. Nephrol., 2003, 14, 1212–1222.
- HIGASHIURA, K., URA, N., TAKADA, T., LI, Y., TORII, T., TOGASHI, N., TAKADA, M., TAKIZAWA, H., and SHIMAMOTO, K. The effect of an angiotensin converting enzyme and an angiotensin II receptor antagonist on insulin resistance in fructose-fed rats. Am. J. Hypertens., 2000, 13, 290–297.
- KURIKAWA, N., SUGA, M., KURODA, S., YAMADA, K., and ISHIKAWA, H. An angiotensin II type 1 receptor antagonist, olmesartan medoxomil, improves experimental liver fibrosis by suppression of proliferation and collagen synthesis in activated hepatic stellate cells. Br. J. Pharmacol., 2003, 139, 1085–1094.
- NAKAMURA, H., INOUE, T., ARAKAWA, N., SHIMIZU, Y., YOSHIGAE, Y., FUJIMORI, I., SHIMAKAWA, E., TOYOSHI, T., and YOKOYAMA, T. Pharmacological and pharmacokinetic study of olmesartan medoxomil in animal diabetic retinopathy models. Eur. J. Pharmacol., 2005, 512, 239–246.
- SAGAWA, K., NAGATANI, K., KOMAGATA, Y., and YAMAMOTO, K. Angiotensin receptor blockers suppress antigen-specific T cell response and ameliorate collagen-induced arthritis in mice. Arthritis Rheum., 2005, 52, 1920–1928.
- SCHMIDT, B., and SCIEFFER, B. Angiotensin AT1 receptor antagonists. Clinical implications of active metabolites. J. Med. Chem., 2003, 46, 2261–2270.
- NEUTEL, J. M. Clinical studies of CS-866, the newest angiotensin II receptor antagonist. Am. J. Cardiol., 2001, 87, 37c–43c.
- OPARIL, S., WILLIAMS, D., CRYSANT, S.G., MARBURY, T.C., and NEUTEL, J. M. Comparative efficacy of olmesartan, losartan, valsartan and irbsartan. J. Clin. Hypertens., 2001, 3, 283–291.
- GILES, T. D., OPARIL, S., SILFANI, T. N., WANG, A., and WALKER, J. F. Comparison of increasing doses of olmesartan medoxomil, losartan potassium and valsartan in patients with essential hypertension. J. Clin. Hypertens., 2007, 9, 187–195.
- BRUNNER, H. R., STUMPE, K. O., and JANUSZEWICZ, A. Antihypertension efficacy of olmesartan medoxomil and candesartan cilexedil assessed by 24-hr ambulatory blood pressure monitoring in patients with essential hypertension. Clin. Drug Investig., 2003, 23, 419–430.
- SMITH, D. H. G. Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension. Drugs, 2008, 68, 1207–1225.
- CHRYSANT, S. G., MARBURY, T. C., and ROBINSON, T. D. Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension. J. Hum. Hypertens, 2003, 17, 425–432.
- FLISER, D., BUCHHOLZ, K., and HALLER, H. Anti-inflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation, 2004, 110, 1103–1107.
- SMITH, R. D., YOKOYAMA, H., AVERILL, D. B., SCHIFFRIN, E. L., and FERRARIO, C. M. Reversal of vascular hypertrophy in hypertensive patients through blockade of angiotensin II receptors. J. Am. Soc. Hypertens., 2008, 2, 165–172.
- STUMPE, K. O., AGABITI-ROSEI, E., ZIELINSKI, T., SCHREMMER, D., SCHOLZE, J., LAEIS, P., SCHWANDT, P., and LUDWIG, M. Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The multicentre olmesartan atherosclerosis regression evaluation (MORE) study. Ther. Adv. Cardiovasc. Dis., 2007, 1, 97–106.
- RITZ, E., VIBERTI, G. C., RUILOPE, L. M., RABELINK, A. J., IZZO, J. L., KATAYAMA, S., ITO, S., MIMRAM, A., MENNE, J., RUM, L. C., JANUSZEWICZ, A., and HALLER, H. Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the randomized olmesartan and diabetes microalbuminuria prevention (ROADMAP) study. Diabetologia, 2010, 53, 49–57.
- IMAI, E., ITO, S., HANEDA, M., CHANG, J. C. N., MAKINO, H., for the ORIENT investigators. Olmesartan reducing incidence of endstage renal disease in diabetic nephropathy trial (ORIENT): rationale and study design. Hypertens. Res., 2006, 29, 703–709.
